Cullinan Therapeutics (CGEM) – Analysts’ Weekly Ratings Updates

Cullinan Therapeutics (NASDAQ: CGEM) recently received a number of ratings updates from brokerages and research firms:

• 10/2/2026 – Cullinan Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/2/2026 – Cullinan Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $35.00 price target on the stock.
• 9/25/2026 – Cullinan Therapeutics had its price target raised by HC Wainwright from $30.00 to $35.00. They now have a “buy” rating on the stock.
• 9/25/2026 – Cullinan Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $40.00 price target on the stock.
• 9/14/2026 – Cullinan Therapeutics had its price target raised by BTIG Research from $39.00 to $40.00. They now have a “buy” rating on the stock.
• 9/13/2026 – Cullinan Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/5/2026 – Cullinan Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/24/2026 – Cullinan Therapeutics was upgraded by TD Cowen to “strong-buy”.
• 8/17/2026 – Cullinan Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $30.00 price target on the stock.
• 8/13/2026 – Cullinan Therapeutics had its price target raised by Wedbush from $39.00 to $42.00. They now have an “outperform” rating on the stock.

Insider Transactions at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $21.57, for a total transaction of $172,560.00. Following the transaction, the insider owned 158,844 shares of the company’s stock, valued at $3,426,265.08. This trade represents a 4.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 8.60% of the stock is owned by insiders.

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer and autoimmune diseases. The company uses a portfolio-based approach to advance targeted therapies and immune-modulating treatments intended to address significant unmet medical needs.

Cullinan’s pipeline includes zovoltamab brengitecan (CLN-978), an investigational CD19-directed T-cell engager being studied in B-cell malignancies and autoimmune conditions, and CLN-619, an investigational antibody designed to target MICA and MICB proteins and stimulate anti-tumor immune responses.